Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease

aTyr Pharma secured formal FDA agreement on the Phase 3 study protocol for efzofitimod, its lead therapeutic candidate. The regulatory alignment reduces development-path uncertainty and supports progression of the company’s late-stage clinical program, though no efficacy, financial, or timeline details were provided.